TS-1 combination granule T20 56bag x 0.2g (Tegafur/Gimeracil/Oteracil Potassium)

Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Taiho Pharmaceutical Co.Ltd
Manufacturer	Taiho Pharmaceutical Co.Ltd.
Prescription required	Yes

Description

TS-1 combination granule T20 56bag x 0.2g(/ /) (Tegafur/Gimeracil/Oteracil Potassium) is a medicine catalog record in the MediPriceHub database. Active ingredient: Tegafur/Gimeracil/Oteracil Potassium. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Taiho Pharmaceutical Co.Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Pack information: 0.2 / 56. Origin country or market: Japan. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

TS-1 combination capsules TS-1 combination granules C8H9FN2O3

How to Use

Use Tegafur/Gimeracil/Oteracil Potassium under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: Tegafur/Gimeracil/Oteracil Potassium. Pack size: 0.2 / 56. Pack unit: box. Manufacturer: Taiho Pharmaceutical Co.Ltd.. Origin country: Japan. Source category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.